If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...
Pharmaceutical Technology on MSN
Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout
If approved, the deal’s centrepiece, PER-001, could continue Bayer’s ophthalmology legacy defined by blockbuster retinal ...
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing ...
TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...
TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient ...
FRANKFURT (Reuters) -Bayer said on Friday that the European Medicines Agency recommended approval of a higher dose version of eye drug Eylea for treatment of a leading cause of blindness among the ...
The German pharmaceutical-and-agricultural group said the acquisition would complement its drug pipeline and leverage its ...
ZURICH (Reuters) - Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results